AgomAb Therapeutics NV American Depositary Shares (AGMB) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US00860C1027

Price
6.97 USD
Market cap
339.70 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-46.81 %
Return on assets (ROA)
-39.87 %

AgomAb Therapeutics NV American Depositary Shares financials

Fiscal year20242025
Revenue0.00 USD0.00 USD
Gross profit0.00 USD0.00 USD
EBIT-55.00 m USD-68.00 m USD
Net income-53.00 m USD-72.00 m USD
Diluted EPS – continuing operations-1.48 USD-1.49 USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.